Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results
2018 Genitourinary Cancers Symposium
Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).
Joaquim Bellmunt, MD, PhD, of the Dana-Farber Cancer Institute, discusses phase III 2-year follow-up findings on pembrolizumab vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (Abstract 410).
Nicholas D. James, MBBS, PhD, of University Hospitals Birmingham NHS Foundation Trust, discusses study findings on the addition of docetaxel to first-line hormone therapy in prostate cancer, an analysis focusing on cost-effectiveness and long-term and quality-adjusted survival (Abstract 162).
Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharmacogenomic analysis (Abstract 576).
Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy in clinical stage I testicular cancer, the impact of Medicaid expansion on diagnosis and management of patients with testicular cancer, and comparative genomic profiling of refractory/metastatic penile and nonpenile cutaneous squamous cell carcinoma (Abstracts 549-552).
Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and how, in the future, this information may help triage patients with aggressive prostate tumors to intensified treatments.